EISAI and Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation for LECANEMAB (BAN2401), an Anti-Amyloid Beta Protofibril Antibody for the Treatment of Alzheimer's Disease

MEDIA CONTACT: Eisai Co., Ltd. Public Relations Department TEL: +81-(0)3-3817-5120 Eisai Inc. Public Relations Department TEL: +1-201-753-1945 libby_holman@eisai.com INVESTOR CONTACT: Eisai Co., Ltd. Investor Relations Department TEL: +81-(0)3-3817-5121 | MEDIA CONTACT: Biogen Inc. Allison Parks public.affairs@biogen.com INVESTOR CONTACT: Biogen Inc. Mike Hencke +1-781-464-2442 IR@biogen.com |